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International regulatory control of medicinal products
and medical devices is in a state of change.  Regulatory
agencies are expected to exert more and more influence
in the interests of patients and consumers. Decisions,
their motivations, and procedures should be transpar-
ent. The ‘control services’ offered to citizens, health care
professionals and the industry should be of the best pos-
sible quality. These factors have resulted in a reorganisa-
tion of the National Agency for Medicines (NAM) and
to its functional development.
The major aspects of NAM’s process of change – the
strategy extending to the year 2006, the reorganisation,
and the Results Agreement for 2003 concluded with the
Ministry of Social Affairs and Health – have been fi-
nalised. It is time to review the concrete objectives of
these changes.
In the international control of pharmaceuticals and
medical devices, the significance of the contribution of
any single state, organisation, or individual may remain
indistinct. That is understandable, if the decisions made
at European Union level are commonly thought to be
made by a distant and obscure organisation, for which
nobody has any personal responsibility. In fact, howev-
er, each decision has been prepared, presented and exe-
cuted by appropriate officials, either collectively in joint
bodies, or at individual level. 
For the control of medicines and medical devices, in-
fluence means having real and actual power to exert in-
fluence on any decisions of relevance, be it on the na-
tional or the common EU level. In terms of medicines
control, most significant decisions are ultimately made
in international co-operation, although national ad hoc
solutions might have been resorted to in the first in-
stance.
For the National Agency for Medicines, exerting in-
fluence implies assuming additional responsibility and
accepting further functions in the regulatory coopera-
tion. The issues should be important for Finnish health
care, and we should have enough top expertise and re-
sources at our disposal. We should ensure that we exert
influence at home in accordance with social affairs and
health care strategies.
What, then, is transparency in terms of the authori-
ties’ operations? I should think it consists mainly of the
grounds for the  decisions adopted being public knowl-
edge, and the operating principles transparent. That will
increase our credibility and public confidence in us.
Much remains to be done in this regard, both by the na-
tional authorities and EU organisations. Transparency is
a growing trend at present, and that is good. The times,
when a regulatory body  was satisfied with decisions be-
ing made formally in the correct order, are something of
the past. 
National Agency for Medicines is advancing in rapid
strides along the road to transparency. The publication
on our web pages of SPCs and PILs, of documents cir-
culated for comments, and even of our rules of proce-
dure, are signs of this trend. Rapid progress is being
made in Europe towards the publication of all state-
ments of scientific evaluation of medicines, as already
practised by EMEA.  
The concept of Clients of the NAM has been defined
in the Results Agreement between the National Agency
for Medicines and the Ministry of Social Affairs and
Health for the first time. It is well worth repeating here:
Citizens needing medicines, medical devices, or blood
products are the ultimate clients of the National Agency
for Medicines. The National Agency for Medicines main-
tains and promotes the safe use of the above-mentioned
products. In practice, this control focuses on the research,
manufacture, sales, distribution, and marketing of medi-
cines and medical devices. In terms of our control func-
tion, our primary clients are entrepreneurs within the in-
dustry. Health care professionals play a crucial role in the
clientele chain.
The control of medicines and medical devices consists to a
great extent of co-operation. Our partners include various
statutory authorities and bodies, research and testing insti-
tutes, international organisations and universities.
The majority of NAM’s clients are paying customers.
They, as well as all the other clients, are entitled to de-
mand from NAM quality services rendered on time and
according to good management principles. The study of
interest groups carried out in 2001 gave valuable clues
on how to improve our services further. We are now on
that road.
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines
Influence, transparency and better service
Editorial
Summary 
Translation Liisa Fellman-Paul
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In addition to problems of human
relationship and difficulties at
school, children with attention
deficit hyperactivity disorder
(ADHD) will also run the risk of
developing complications such as
anxiety, addiction and an affective
syndrome in their later years of life.
Besides psychosocial methods of
treatment, the treatment of ADHD
has consisted of psychotropic drug
therapy with stimulants and partly
with dual-action antidepressants.
This review will focus on the treat-
ment of ADHD and particularly the
use of stimulants.
ADHD was reported for the first
time in 1901 (see Solanto et al.,
2001), and its recognition and treat-
ment have been widely studied ever
since. The diagnosis is based on the
recognition of the clinical symp-
toms. The ICD-10 classification of
hyperkinetic disorders (Stakes,
Finnish Research and Development
Centre for Welfare and Health,
1997) is outlined in Table 1. The
diagnostic classification DSM-IV is
accepted as the appropriate classifi-
cation to use in USA and is therefore
also included in Table 1. Back-
ground information on the patient
given by the parents and the school
is of key importance in the diagno-
sis. A structured interview can be
helpful in the collection of such
information (Aronen, 2000). Atten-
tion disorder and hyperactivity are
considered the core symptoms of
ADHD, and the disadvantages
become apparent even as early as
before the age of seven. A later start
for the affliction, at the age of 7–9,
has been described in some sub-
states of the disorder (Erkolahti and
Piha, 1998, Solanto et al., 2001).
It is suggested that the prevalence
of ADHD in 6–15-year-olds is 3–
5%. Epidemiological studies show it
to be more prevalent and more com-
plicated in boys; boys are reported
to be afflicted with the disorder 2–9
times more commonly than girls
(Puura et al., 1998). ADHD occurs
in two or more life situations, usual-
ly at home and at school. It is a
long-term disorder associated with
significant deterioration in cognitive
and social skills and achievement at
school. Patients with ADHD are
often found to suffer from other
concomitant disorders such as learn-
ing difficulties, oppositional defiant
disorder, anxiety and affective syn-
drome. Long-term follow-ups have
also revealed associated socio-eco-
nomic complications later in life,
and a considerable number of con-
currently occurring illnesses, espe-
cially in relation to anxiety, addic-
tion, personality disorders and affec-
tive syndrome. Antisocial personali-
ty disorder and addiction problems
may later in life be more usual in
children with a behavioural disorder
in addition to their ADHD (Bieder-
man et al., 1996, Räsänen 1999).
ADHD has been reported to contin-
ue into adulthood in 10–60% of
patients (Biederman et al., 1993).
ADHD is more common in the
close relatives of children receiving
treatment than in the relatives of
other children, which is an indica-
tion of the significance of genetic
factors in the development of the
disorder (Solanto et al., 2001). Gene
studies are focused on the genes,
which regulate the dopamine and
noradrenaline-mediated nerve func-
tion (e.g. dopamine transporter and
dopamine-4 receptor genes, and
noradrenaline-mediated alfa-2a and
-2c receptor genes). This is because
the regulation disturbance located in
the prefrontal and striatal area of
the dopamine system is considered
to be of key importance to the
development of ADHD. In addition,
the regulation disorder of the nor-
adrenaline-mediated nerve function
is also of importance as it affects the
state of alertness, for example. In
fact, the effect of methylphenidate
and dextroamphetamine therapy is
considered to consist of decreasing
both the dopamine and noradrena-
line re-uptake in the nerve ends, in
Hannu Koponen
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The use of stimulants in attention deficit hyperac-
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Summary 
Table 1 .  Classi f icat ion of  hyper-
kinet ic  disorders  
ICD-10 
F 90.0 ADHD
F 90.1 Hyperkinetic conduct disorder
F 90.8 Other hyperkinetic disorders
F 90.9 Unspecified hyperkinetic disor-
der
DSM-IV 
ADHD, combined type
ADHD, mainly attention deficit type
ADHD, hyperactive/impulsive type
Unspecified ADHD
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addition to which dextroampheta-
mine also increases the release of
dopamine and noradrenaline (Solan-
to et al., 2001).
Various psychosocial treatment
models have been developed for
treating ADHD, with the aim of
reducing the disadvantages occa-
sioned by the disorder at school and
in the family circle (Multimodal
Treatment Study of Children with
ADHD, or MTA Co-operative
Group 1999a). In addition, the use
of psychotropic drug therapy with
stimulants and to a certain extent
also with antidepressants (e.g.
desipramine and venlafaxine) has
increased in moderate and severe
cases. Superior results have been
achieved with concurrent use of
both therapies above (MTA Co-
operative Group 1999b). The stim-
ulants, short-acting methylphenidate
and dextroamphetamine, are in use
in Finland at present by special
authorisation. This review focuses
on the results of studies published
on the various possible uses of stim-
ulants, particularly in the treatment
of ADHD. Other indications for
stimulants, such as narcolepsy, 
treatment-resistant depression or
apathy caused by a common illness
(AACAP 2002), are not discussed.
Treatment of ADHD 
The most important aims in the
treatment of ADHD consist of alle-
viating  the behavioural disturbance,
and improving the quality of inter-
action between parent and child and
the social skills of the patient. By
palliating  the core symptoms of
ADHD, anxiety associated with the
disorder will also be alleviated
(MTA Co-operative Group 1999b).
The primary alternatives of treat-
ment in mild and moderate cases in
the prevailing  European clinical
practice are psychosocial treatment
methods, coupled  with medical
treatment in severe cases (Aronen
2000). Based on the assessment of
the results of the MTA study it
could be accepted that medical treat-
ment could  nevertheless also be
given to patients with an inadequate
response to behavioural therapy or
otherwise in need of more effective
treatment. Concurrent administra-
tion of medical treatment and
behavioural therapy have proven
more effective than behavioural
therapy or community therapy alone
(Taylor 1999, MTA Co-operative
Group 1999a). The drug doses used
in combination therapy have been
smaller than when using drug thera-
py alone (MTA Co-operative Group
1999a).
Psychosocial therapy of ADHD
Since the occurrence of ADHD
symptoms is influenced both by
stress and psychosocial stress fac-
tors, various psychosocial treatment
methods have been developed, such
as support and guidance given to the
parents, the child and the school.
Based on behavioural therapy, a sys-
tem of rewarding the desired calm
behaviour could also be used, as
well as some of the more specific
therapies such as cognitive or pscy-
hodynamic individual therapy or
family therapy (MTA Co-operative
Group 1999a, Aronen 2000). Psy-
chosocial treatment methods are
generally approved by families, and
the percentage of patients disrupting
their treatment in the MTA study
(USA), for example, was only 3.5
percent (MTA Co-operative Group
1999a).
Medical treatment
The effectiveness of medical treat-
ment of ADHD with stimulants has
proven in several studies to be supe-
rior to that of a placebo. The num-
ber of patients participating in clini-
cal drug trials has been considerably
higher than in other fields of psychi-
atric therapy, and the efficacy of
stimulant therapy can be considered
unequivocally as proven. Stimulant
therapy is generally not recommend-
ed before the age of six. The first
symptoms of the disorder may nev-
ertheless appear as early as prior to
the age of three. Further studies
would be required especially in the
treatment with psychostimulants of
children of pre-school age.
The USA drug authority FDA
approved the use of stimulants for
the treatment of ADHD more than
20 years ago. The time- and coun-
tryspecific differences in stimulant
use vary greatly. For example, in the
USA the use of stimulants has
increased five-fold during the 1990s,
and the differences in the use of
stimulant therapy between different
countries are significant, being as
high as 10 to 30-fold in comparison
(Taylor, 1999). In the general discus-
sion on stimulant therapy, concern is
expressed about the development of
drug dependence later in life; it has
been suggested that long-term stimu-
lant therapy is a cause of an
increased risk especially of cocaine
and nicotine dependence. The results
of studies in the field are neverthe-
less contradictory, and a decreased
risk of drug dependence has also
been reported. An increased risk of
dependence has also been reported
in untreated patients or patients
with a poor response to treatment
(Solanto et al., 2001). About one
percent of patients on stimulant
therapy in the USA have gone over
to the use of drugs, and drug addic-
tion has been most common among
adult users of mixed therapies.
The proportion of patients bene-
fitting from stimulant therapy in
various trials has been between 65%
and 95% when the accepted
response criteria included reduced
motor restlessness, less disturbed
behaviour and improved social rela-
tionships. The same studies reported
a 4–30% response to a placebo. The
state of alertness and reaction time
are improved by medical treatment,
and the response is dose dependent.
Good response to medical treatment
can be anticipated when the follow-
ing criteria are fulfilled: young age,
state of low anxiety, higher degree
of severity of symptoms and high
intelligence quotient. As regards the
underlying criteria expected, howev-
er, study results vary and the expec-
tations at the level of the individual
are unreliable. Response to treat-
ment does not appear to differ
between the two sexes (MTA Co-
operative Group 1999). Approval of
the medical treatment by the
patient’s family is an important con-
dition of success, and inadequate
treatment compliance is considered
a contraindication for stimulant
therapy (Läkemedelsverket 2002).
Previous predictions alleged that the
response to stimulant therapy might
disappear due to the tolerance devel-
oped on long-term use, but this is
not confirmed by more recent stud-
TABU 6.2002 45
ies. Opinions on the necessary dura-
tion of stimulant therapy vary, but
ADHD is a long-term disorder,
which may need years of treatment
despite varying severity of the symp-
toms. Further studies would be nec-
essary on long-term treatment of
ADHD, since withdrawal of the
medication appears to wipe out the
positive effects of the stimulant ther-
apy (Solanto et al., 2001).
Methylphenidate
The drug most commonly used in
stimulant therapy is short-acting
methylphenidate. The daily dose in
different studies has varied between
0.3 and 1.2 mg/kg, and the usual
dosage of the short-acting formula
has been 3 times daily (at about 8
a.m., 12 noon and 4 p.m.). The
interval between administrations
should be about four hours to avoid
reduced efficacy, and an afternoon
dose is recommended to avoid
rebound effects due to cessation of
the effect of the drug.
One of the biggest impediments
to the use of the short-acting formu-
la is considered to be the fact that it
ought to be taken during the school
day as well, which may make its
regular use more difficult. Longer-
acting drug forms have therefore
been developed to facilitate adminis-
tration (Pelham et al., 2002).  The
response to the dose varies signifi-
cantly between individuals; conse-
quently, individual adjustment of the
dose once a month according to the
patient’s tolerance to treatment and
the degree of alleviation of the most
complicated symptoms is considered
the most appropriate approach in
clinical use.
The most common adverse reac-
tions reported for methylphenidate
are sleep disturbances, stomach
pains, headache, increased irritabili-
ty and occurrence of involuntary
movements or tics. Tics are caused
by the dopamine-agonistic effect of
methylphenidate and their presence
in the patient or the patient’s near
relatives is considered a contraindi-
cation for methylphenidate therapy,
even if rare and mild symptoms of
tic are not regarded as preventing
continued treatment. Stimulants
reduce the growth rate, and an
interruption of the medication dur-
ing weekends is therefore recom-
mended. Development of psychosis
is very rare, but previous or present
symptoms of psychosis are consid-
ered a contraindication for stimulant
therapy. Other contraindications
include glaucoma, hyperthyroidism,
hypertension or other symptomatic
heart disease or pregnancy (Läke-
medelsverket 2002, AACAP 2002).
Stimulants have been found to
reduce the threshold of spasms, even
though this effect is minor with the
doses used to treat ADHD. Howev-
er, the use of stimulants in children
with previous epileptic seizures
requires concurrent anti-epileptic
therapy. Nevertheless, adverse reac-
tions associated with stimulant ther-
apy (Table 2) are generally mild and
can be reduced in intensity by a
reduction in the stimulant dose.
Adverse reactions have caused the
withdrawal of stimulant therapy in
about 4% of patients.
Other stimulants
Dextroamphetamine has been used
somewhat at the dosage rate of
0.15–1.0 mg/kg/day in two divided
doses.  Tolerance to the cardiovascu-
lar, appetite-reducing and mood-lift-
ing effects of dextroamphetamine
will be induced in the patient during
the weeks following introduction of
the drug. Two stimulants (methyl-
phenidate and dextroamphetamine)
were used concurrently in individual
trials, and the percentage of the
patients not benefitting from the
stimulant therapy remained at 4%;
nevertheless, the concurrent use of
two stimulants cannot be considered
as common clinical practice.
Other medical treatments
In addition to methylphenidate,
ADHD has also been treated with
other drug therapies. In a small trial,
the effects of MAO inhibitors, clor-
gyline and tranylcypromine were
shown to be equal to that of dex-
troamphetamine. However, MAO
inhibitors and stimulants should not
be used concurrently due to the risk
of a hypertensive crisis. Tricyclic
antidepressants, chlorpramine,
imipramine and desipramine, were
shown to be effective in the treat-
ment of ADHD, even though their
efficacy was inferior to that of
methylphenidate (Wilens et al.,
1996). They have the adverse effects
of tricyclic antidepressants, and
more recently dual-action antide-
pressants such as venlafaxine have
therefore been used as antidepres-
sant medication in ADHD. If intol-
erance to stimulants occurs, the sug-
gested alternative medication in
addition to antidepressants is cloni-
dine; it achieves a slower response,
however, compared with the groups
of drugs mentioned above. Prelimi-
nary trials of other noradrenergic
preparations such as tomoxetin have
shown themselves to be effective in
the treatment of ADHD (Spencer et
al., 1998).
Conclusion
Full use of the possibilities offered
by the medical treatment of ADHD
requires a reliable system of assess-
ment and a setup of guidelines for
treatment appropriate for the condi-
tions in Finland. This is especially
necessary as the principle of the
action of stimulants is different from
that of the psychotropic drugs in use
at present, and knowledge of the
special characteristics of the prepar-
tions in the group is required (Erko-
lahti and Piha 1998, Taylor 1999,
Aronen 2000). Medical treatment of
this patient group can be facilitated
by the new long-acting methylphen-
idate. Drugs under development
with an effect on the noradrenaline-
mediated nerve function can in the
near future diversify the selection of
drugs available at present.
Table 2.   Adverse react ions as-
sociated with st imulant  therapy
Common react ions
- headache
- stomach pains
- sleep disturbances
- increased irritability
- involuntary movements or tics
Rare react ions
- psychosis
- loss of hair
- rash
- liver damage (pemoline) 
- epileptic seizures
- palpitations
- hypertension
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Several underlying factors may cause
non-specific pain in the mouth and
tongue. This article focuses on the
most common conditions which
cause pain and on the burning
mouth syndrome.
Variations in normal anatomy
Fissured tongue, lingua plicata
Fissures can be seen on the surface
of the tongue in about five percent
of the population. The number of
fissures and their depth may vary .
Microbial matter readily accumu-
lates in the fissures, and the tongue
consequently easily becomes in-
flamed. Smarting pain occurs in the
inflamed tongue, which may even be
slightly swollen. The treatment of an
inflamed fissured tongue consists of
cleansing of the fissures with a
toothbrush or by using a special
plastic spatula designed for the
cleansing of the tongue (1).
Benign migratory glossitis, lingua
geographica
Benign migratory glossitis is found
in about two percent of the popula-
tion. It consists of change of un-
known origin in the mucous mem-
brane of the tongue and it is occa-
sionally known to be associated for
example with stress, oral fungal in-
fection, psoriasis and asthma. Be-
nign migratory glossitis is often also
associated with fissured tongue. The
clinical signs consist of red, irregular
blotches surrounded by a light yel-
lowish edge.  The blotches on the
tongue typically change place, hence
the name migratory glossitis (1, 2).
Benign migratory glossitis is of-
ten symptom-free, but certain food-
stuffs can occasionally cause smart-
ing (1). No treatment is usually re-
quired. A topical mild corticosteroid
may be prescribed for smarting le-
sions if necessary.
Aphthae
After traumata, aphthae are proba-
bly the most common cause of oral
pain. Depending on the study, the
prevalence of aphthae is 20–60% in
the population overall. The etiology
of aphthae is unknown at present.
Several possible factors have never-
theless been studied (Table 1).
Aphtha minor is the most com-
mon form of aphtha. The changes of
recurrent aphthous stomatitis (RAS)
also follow this pattern. Typically, a
sore, oval shaped 1-cm lesion is
seen, which is covered by yellowish
fibrinous coat. Occasionally there
may be several lesions at the same
time. Changes may occur almost
anywhere in the oral mucous mem-
brane, but never on the adjoining
gums or the palate. Aphtha minor
heals on its own within about a
week and does not leave scars.
The lesions caused by aphtha
major (or Sutton’s disease) are big-
ger than those caused by aphtha mi-
nor; their diameter varies between
one and two centimetres. Single le-
sions may occur, or as many as ten
of them may occur at the same time
in the mouth. The lesions are very
sore and slow to heal. Lesions
caused by aphtha major will leave
scars after healing.
Herpetiform aphtha is the term
used for small aphthous lesions
(with a diameter of 1–2 mm) occur-
ring in groups. Herpetiform aphtha
may occur anywhere in the oral mu-
cous membrane, i.e. including the
gums and palate. These lesions heal
by themselves within about a week,
and do not leave scars.
If the patient suffers from recur-
rent aphthous stomatitis, the possi-
bility of an underlying systemic dis-
ease should be investigated. The pa-
tient should be interrogated about
other possible symptoms such as
those involving the digestive tract,
foodstuff allergies, diet, and other
more generalized conditions, e.g.
bouts of fever. Elderly patients in
particular should be examined to es-
tablish serum vitamin B12, iron and
folate values to exclude anaemia.
Unless anything unusual is detected
on medical or dental examination,
medication may be tried in the treat-
ment of aphthae (3).
Treatment of aphthae is aimed at
alleviating the pain and shortening
the duration of the lesions. The topi-
cal treatments most frequently tried
include the application of triamci-
nolone acetonide, anaesthetising
ointments and chlorhexidine mouth-
washes. Since the sodium lauryl sul-
phate contained in most toothpastes
may denature the oral mucous mem-
brane and thereby promote the de-
velopment of lesions, patients with
aphthae should avoid the use of
toothpastes which contain this com-
pound. Systemic glucocorticoids,
pentoxyphylline, thalidomide and
Pain in the oral mucous membranes
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Table 1.   Factors possibly underly-
ing the occurrence of  aphthae (3)
Deficiencies
vitamins B1, 2, 6, 12, iron, folate 
Hypersensivity reactions
e.g. to benzoic acid
Genetic predisposition
Viruses (herpes, measles)
Behçet’s disease
Haematological disorders
erythrocyte changes
Gastrointestinal diseases
Crohn’s disease, celiac disease, 
ulcerative colitis
Hormonal factors
menstrual cycle
Trauma
Certain medicinal substances
anti-inflammatory analgesics,
chemotherapy
Immune deficiency
HIV, leukaemia
Stress
Summary 
tetracycline or cephalexin mouth-
washes have also been tried on ex-
tremely complicated aphthous oral
inflammations. It should be borne in
mind, nevertheless, that systemic
treatment of aphthae is in no way
routine treatment (3, 4)!
Deficiencies
Among deficiencies, iron and vita-
min B12 deficiencies are the most
common conditions causing changes
and symptoms in the oral mucous
membrane. Iron deficiency has an
effect on the development and
growth of all cells. In the mouth,
iron deficiency anaemia is manifest-
ed as mucous membrane epithelial
atrophy. Typically, this shows up as
atrophy of the lingual papillae and
stomatitis at the corners of the
mouth. Iron deficiency anaemia is
treated with oral iron supplements
for a period of four to six weeks.
The body’s iron stores are replen-
ished within just over two months,
but the mucous membranes take a
longer time to heal (1, 2).
Vitamin B12 and/or folate defi-
ciencies cause a disturbance in DNA
synthesis. This is manifested as
macrocytosis of the oral mucous
membrane epithelial cells. The clini-
cal manifestations are usually a red
and smooth tongue, which is also
painful. Deficiency of vitamin B12 is
treated with vitamin supplements
The cause of deficiencies should also
be established, and the possibility of
e.g. coeliac disease or pernicious
anaemia should be excluded (1, 2).
Common diseases
Several common diseases can cause
pain in the oral mucous membranes.
A list of these diseases is shown in
Table 2.  
Lichen planus is a relatively com-
mon disease of the skin and mucous
membrane, the cause of which is so
far unknown.  It is nevertheless as-
sumed to be caused by a cell- medi-
ated immune response to either an
external or an allogenic antigen.
About two thirds of the sufferers are
women, and the disease occurs pri-
marily in 40–60-year-olds. In addi-
tion to mucous membrane symp-
toms, 20–60 % of lichen sufferers
also exhibit skin changes, and about
half the patients with lichen planus
also have a secondary fungal inflam-
mation of the mouth. Typically, the
skin changes are periodical, but the
changes in the oral mucous mem-
branes are long-term. The clinical
picture of lichen in the oral mucous
membranes is very varied, and it is
divided into six main types: papular,
reticular or net type, plaque type, at-
rophic, erosive and bullous type (5).
The most common of these is the
reticular type, and features of sever-
al lichen types are often found in the
changes in the mouth. It should be
borne in mind that a definitive diag-
nosis of lichen can never be made on
the basis of a clinical manifestation
alone, and the diagnosis needs to be
confirmed by biopsy.
A frequent symptom of lichen
planus is a periodic stinging sensa-
tion in the oral mucous membranes.
Certain foodstuffs, such as tomatoes
and citrus fruit, typically provoke
the sensation. The clinical picture of
lichen does not always coincide with
the patient’s symptoms. It needs also
to be taken into account that the
symptoms of a lichen patient are ex-
acerbated if the patient has an oral
fungal infection.
Treatment of lichen planus con-
sists mainly of treating the symp-
toms and the inflammation. Topical
corticosteroids are the therapy most
commonly used at present. These
are administered as a course of
treatment (5). Untreated fungal in-
fection of the mouth is a contraindi-
cation to starting corticosteroid
treatment of lichen. As there are
very few placebo-controlled studies
of medical treatment of lichen, the
superiority of any one treatment
compared with any other is difficult
to establish (6).
Burning mouth syndrome
If no explanation for the patient’s
pain in the mouth is found despite
careful studies, it may be a case of a
burning mouth syndrome. Patients
with a burning mouth syndrome.
are typically postmenopausal
women, and   the majority suffer
from anxiety, depression or even
personality disorders. The symptom
complained of is a burning, symmet-
rical pain, which is usually located
in the tongue. The pain becomes
worse towards the evening, but
drinking or eating usually alleviates
it (7).
Burning mouth syndrome has
been treated as if it were a psycho-
somatic disorder. More recent stud-
ies have nevertheless revealed somat-
ic states possibly causing this syn-
drome. It has been suggested that a
large number of papillae fungifor-
mae on the tip of the tongue consti-
tute a predisposing factor for the
syndrome. The larger the number of
papillae, the more strongly the irri-
tation of the taste nerve experienced.
The sense of taste may change dur-
ing menopause, and  these changes
can alter the function of the chorda
tympani so that its inhibiting effect
on the trigeminal nerve is reduced.
The trigeminal nerve mediates the
sensation of touch and pain from
the area of the mouth, and conse-
quently, these sensations are empha-
sised. Any trauma suffered by the
chorda tympani may of course also
cause a reduction in the inhibition
(7). The fact that the pain is relieved
when the area is anaesthetised is al-
so an indication of the neuropathic
cause of the pain. Patients with
burning mouth syndrome have also
frequently been found to have a low
vitamin B12 level in the blood. It
may well be the case, therefore, that
anxiety and depression often associ-
ated with the disease are after-effects
of the pain, and not its cause.
Burning mouth is very difficult to
treat. Good results in the treatment
of burning mouth have been ob-
tained with vitamin supplements, es-
pecially vitamin B supplements (9.
Psychotherapy has also been tried as
a treatment due to the possible men-
tal component associated with the
disease (7).
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Table 2.   Common diseases,
which can cause pain in  the oral
mucous membranes
Diabetes
Lichen planus
Erythema multiforme
GI-diseases (Crohn’s disease, 
coeliac disease) 
Vesicular diseases (e.g. HSV)
Neurological disorders
Connective tissue diseases (e.g. SLE)
Malignant tumours
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Conclusion
Pain in the oral mucous membranes
is a relatively common ailment. The
cause of the pain may well be easily
found by taking a look in the pa-
tient’s mouth. However, more exten-
sive examinations are often more
usually required in order to establish
the cause. It also needs to be borne
in mind that the pain could be a pri-
mary symptom of oral cancer.
The treatment of the most com-
mon changes in the oral mucous
membranes is most practically given
by a dentist, but the most complicat-
ed cases of mouth pain are attended
to in central hospitals, usually in de-
partments for oral diseases. The col-
laboration of several medical spe-
cialists and/or dentists is often re-
quired in the treatment of compli-
cated cases of pain.
I would like to express my gratitude
to Professor Tuula Salo for her valu-
able comments.
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Report of an adverse reactions
An insulin-treated diabetic pa-
tient, vascular surgery and prot-
amine – a predictable outcome?
Petri Kivinen
SENIOR PHYSICIAN
Dept. of Dermatology
Kuopio University Hospital
What is protamine?
Protamine is the general term for
very basic proteins with a molecular
weight of 4–7 kDa containing 60%
of arginine; they are also bound to
the DNA in the germ cells as a so-
called nucleoprotamine in almost all
vertebrates. In mammalian cells prot-
amine is found only temporarily in
the decondensation of the sperm nu-
cleus (Shimada et al. 2000). It occurs
especially in spawners such as
salmon, trout, herring, cod, sturgeon
and mackerel. In men, protamine is
found in the nucleus of the sperm
(Samuel et al. 1978).
What about protamine sulphate?
Sulphonated protamine is used in in-
sulin to prolong its effect: insulin is
tightly bound to it and is then re-
leased slowly, which produces “long-
acting insulins”, especially the so-
called NPH insulins. One NPH in-
sulin, for example, contains 0.348
mg of protamine sulphate corre-
sponding to 0.270 mg of protamine
base/100 IU of insulin. Protamine is
also used as bolus injection in
surgery as a heparin antagonist; the
most common dosage then used is 
1 mg of protamine/100 IU.
What adverse reactions are
caused by protamine sulphate?
Anaphylactic shock was one of the
first reported adverse reactions of
protamine in humans (Nordström L
et al. 1978). Later over 100 prota-
mine-induced deaths have been re-
ported in the literature (Tsui et al.
2001). Protamines have been found
to be highly immunogenic; subcuta-
neous insulin injections containing
protamine and intravenous injections
of even small doses will start the pro-
duction of protamine-specific IgE
and IgG antibodies (Weiss et al.
1989, Nyhan et al. 1996). Adverse
reactions of intravascular administra-
tion of protamine have included red-
ness of the skin, urticaria, broncho-
spasm, pulmonary hypertension, sys-
temic hypotension, pulmonary oede-
ma and sometimes, but rarely, even
death (Horrow 1985, Weiler et al.
1985). Adverse reactions are trans-
mitted via several various mecha-
nisms, such as type I allergy, comple-
ment activation and direct release of
histamine (Horrow 1985, Weiler et
al. 1985).
Diabetics treated with NPH in-
sulins have been found to be at a
10–30-fold risk of anaphylaxis when
heparinisation is reversed (Lewy
1992). The incidence of anaphylaxis
in diabetics is in the range of 0.6–2%
and mortality as high as 40% (Lewy
et al. 1986). Desensitisation of pa-
tients with insulin allergy may acci-
dentally also produce IgE-mediated
protamine allergy (Bollinger et al.
1999). In infertile and vasectomised
men, anti-protamine activity may in-
crease the risk of anaphylaxis
(Samuel et al. 1978); the same ap-
plies to patients with iodine, shellfish
and fish allergies (Kimmel et al.
1998). Patients who have previously
undergone vascular operations also
have a greater risk of anaphylaxis,
but an anaphylactoid reaction with-
out earlier predisposing factors is al-
so a possibility (Peng et al. 2000).
Platelet and blood transfusions are
nevertheless more frequent causes of
adverse reactions in surgery than si-
multaneously administered prota-
mine (Lewy 1992).
A case study 
A 65-year-old female with LADA type
diabetes for the past 20 years, and al-
so with mild nephropathy, hyperten-
sion, coronary artery disease and car-
diac insufficiency.
Three months prior to her hospital
visit, small, bluish, blotchy lesions
had developed in both her calves sur-
rounded by a highly reddened area of
skin and with a tight tectorial mem-
brane over the lesion. The lesions had
become larger despite appropriate
topical treatment. The patient was
hospitalised to improve the topical
treatment and to find the cause of the
lesions. Prior to results of laboratory
tests and biopsies the patient was
treated for suspected vasculitis and,
after tests respecting her diabetes, she
was given prednisolone 20 mg x 1.
Vasculitis was not indicated by biopsy
results, however, and the dosage of
prednisolone was gradually reduced.
Despite effective treatment, the lesions
became worse during hospital treat-
ment, and an angiography of the low-
er limbs revealed a diffuse, serious ar-
terial stenosis of the lower limbs distal
to the level of the thighs. ASO was es-
tablished as the cause of the lesions,
the predisposing factor being long-
term diabetes. Adequate results were
not produced by PTA measures, and
consequently extensive vascular
surgery was performed in the form of
arterial bypasses in both lower limbs.
The operation was technically suc-
cessful, but to reverse heparinisation
the patient was given 1 mg of prota-
mine sulphate at the end of the opera-
tion, and she thereupon rapidly be-
came extremely hypotensive. The pa-
tient’s emergency treatment consisted
of an intravascular dose of 250 mg of
hydrocortisone administered in re-
sponse to the assumed allergic reac-
tion. The administration of phenyle-
phrine was initiated in order to cor-
rect the hypotension, but despite this,
the patient’s pulse rate was reduced
and she quickly lost consciousness.
The patient was intubated, assisted
respiration was commenced, and the
patient was given 2 mg of adrenaline
in addition. As a result of the adrena-
line the patient developed ventricular
fibrillation, which was corrected by
defibrillation. The patient was also
initially given an infusion of dopam-
ine, which was changed to dobuta-
mine when she was transferred to in-
tensive care. By the following morn-
ing the patient had once more had a
series of ventricular fibrillations
which settled on defibrillation. By this
time, the patient had received repeat-
ed doses of adrenaline, 11 ampoules
in total, 13 litres of clear replacement
fluids, 5 litres of blood, 0.5 litres of
thrombocytes and 1 litre of fresh
frozen plasma.
When the patient was transferred
to a ward after 5 days of intensive
care, the insulin mixtures hitherto
used by her were changed to prota-
mine-free preparations in the form of
multi-injection treatment: 10+10+10
IU of protamine-free short-acting in-
sulin (biosynthetic, human) and 20 IU
of long-acting protamine-free zinc-hu-
man insulin-suspension (of recombi-
nant DNA origin) administered at
night. Treatment with insulin-glargine
was also planned for the patient but
there was no time to carry it out due
to difficulties with the supply of the
product. Skin grafts were performed
on the lesions, and the patient left the
hospital about two months from the
date of arrival. The patient suffered a
fatal acute extensive myocardiac in-
farction about two weeks later.
Since the reaction was exception-
ally strong, previous indications of al-
lergy were investigated following the
episode. The patient did not exhibit
any indicative signs and was unable
to tell of any, so the situation came as
a surprise to everyone involved. It
was not until after the adverse effect
that the patient remembered there
having been complications with the
use of insulins. The diabetes outpa-
tient department also had a mention
in their records of 1984 of the devel-
opment of extensive itchy blisters,
which were not caused by needle in-
jections alone. Brands of insulin had
been changed repeatedly through the
years until the appropriate insulin
mixture was found which did not
cause a blister reaction.
Hypersensitivity reactions – 
how common are they?
Hypersensitivity reactions associated
with surgical procedures are rare, de-
spite the fact that a patient usually re-
ceives several different medicinal sub-
stances over a short period of time. In
different reports, the number of reac-
tions has been estimated at 5–250 per
100,000 anaesthesias administered
(Langerh et al. 1982, Fisher et al.
1984), and the rate of mortality has
been estimated at 4–6% (Langerh et
al. 1982, Charpin et al. 1988). The
reactions may nevertheless be serious
and caused by allergy. The patients
may later face new procedures, and to
avoid risks, previous reactions and
their causes ought to be investigated.
In our case, the cause was evident –
or, was it, after all? The patient had
avoided fish and shellfish due to their
taste, but no allergy to them had been
detected. The patient had not been
found to have significant resistance to
insulin, and her diabetic treatment
balance was good. The protamine-
RAST measured about a month after
the incidence was rather low, 0.6
IU/litre and S-IgE was previously nor-
mal. As the patient died soon after
her stay in the ward, final confirma-
tion could not be carried out. On the
basis of this information, however, the
reaction would have best fitted in
with a strong anaphylactoid reaction,
whereas reactions at the injection site
and the rapid onset of the reaction
would support a type I reaction.
How is a diagnosis
arrived at?
Anaphylaxis is defined as a sudden,
serious IgE-mediated hypersensitivity
reaction, the symptoms of which ap-
pear within a couple of minutes;
whereas an anaphylactoid reaction is
independent of specific sensitisation
and its symptoms are dependent on
several transmitters released from the
mast cells without antibody reactions.
To distinguish an anaphylactic and an
anaphylactoid reaction from each oth-
er at the time of occurrence is practi-
cally impossible, but later allergologi-
cal examinations aim to establish the
reaction in question. 
Tests aimed at predicting life-
threatening reactions have not been
developed as yet, and the patient’s
medical history remains the only way
of obtaining information beforehand.
The decision remains with the anaes-
thetist and the surgeon on whether
heparin replacements should be given,
or whether the natural metabolism of
heparin should be awaited. Special
care is nevertheless recommended in
the treatment of diabetics, and it is
advisable that investigation of prota-
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mine allergy should be considered be-
fore extensive vascular surgery.
What should be done if protamine
allergy is detected?
Avoidance is one alternative – by us-
ing non-protamine insulins, a couple
of which are available on the market
– insulin-glargine would be the most
appropriate choice among the long-
acting insulins in multiinjection treat-
ment. Reduced anticoagulation in
surgery is not always feasible, e.g. in
vascular surgery. Hence, heparin re-
moval devices and various heparin
removal filters etc. have been devel-
oped  (von Segesser et al. 2001, Jeg-
ger et al. 2000). Common to all of
them is their high price and the lack
of experience. The most modern
treatment alternatives tried include
anti-TNF-α-antibodies which prevent
the protamine-induced release of
TNF-α and therefore also the car-
diotoxicity of protamine (Pevni et al.
2001). As one alternative, heparin-
degrading heparinase I has already
progressed to phase 3 studies (Heres
et al. 2001). Low-molecular prota-
mine is also a promising subject of
study (Tsui et al. 2001). Alternatives
used e.g. in the treatment of patients
with antibody-mediated heparin
thrombocytopenia, such as lepirudin,
danaparoid, tirofibane, iloprost and
epoprostenol, all of them worthily
discussed elsewhere (von Segesser et
al. 2001), may be considered, based
on the judgement of the anaesthetist
and the surgeon. However, serious
anaphylactic reactions to lepirudin
have been reported. If time allows,
the least complicated approach
would seem to be to wait for the he-
parin to be metabolised normally: the
most common plasma half-life is 90
± 30 min (depending on the dosage –
it is prolonged as the dose is in-
creased). It should be borne in mind
that the time span with heparin de-
rivatives is considerably longer than
with heparin.
Conclusion
All serious reactions should be re-
ported to the ADR register including
also those with known causes. 
Accidentally developed sensitisa-
tion to protamine in insulin tolerance
treatment should be borne in mind,
albeit the cases are rare. In outpatient
care it is also important to take note
of injection site reactions in diabetics
on insulin therapy. If reactions occur
and vascular surgery is planned, it is
recommended that allergy tests be
carried out to examine the type of
the reactions, or that information on
the suspected allergy be included in
the patient referrals. If operations are
necessary, heparin substitutes could
be used, for example, to avoid rare
but even more complicated reactions.
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Reports on suspected adverse drug
reactions (ADR) are an important
part of pharmacovigilance. The re-
ports offer information on severe
and unexpected adverse reactions,
which are not detected in clinical tri-
als (1).
In many countries pharmacists
play an important role in the report-
ing of suspected adverse reactions.
The National Agency for Medicines
in Finland is often asked why phar-
macists are not allowed to report
adverse reactions. This study con-
centrates on the difference in prac-
tice that prevails regarding the ADR
reports submitted by pharmacists
and doctors. Would it change any-
thing if the pharmacy personnel
were given the right to report
ADRs? For this study I made a com-
parison of reports submitted by peo-
ple with pharmaceutical training
and by medical doctors in the
Netherlands during 1995–2000.
In this study, “people with phar-
maceutical training” refers to people
with a higher academic qualification
in the Netherlands. A 6-year Diplo-
ma in Pharmacy in the Netherlands
corresponds to the MPharm degree
in Finland. For the sake of clarity,
the term MPharm is used here.
In Finland, ADR reports are sub-
mitted by doctors and dentists to the
ADR register of the National
Agency for Medicine (2). The
Netherlands Pharmacovigilance
Foundation, or Lareb, maintains the
ADR register in the Netherlands.
Since 1984 MPharms have reported
suspected adverse reactions to
Lareb. They also play a kind of me-
diating role in the reporting of
ADRs by the doctors (3).
The study aimed at reviewing the
possible differences between the re-
porting practice of MPharms and
medical doctors. I investigated the
type of adverse reactions both
groups reported, the drugs involved
and the proportion of serious ad-
verse reactions.
Material and methods
The study material consisted of the
information reported to the register
of Lareb. A single report could con-
tain details of several different
drugs, which were suspected of hav-
ing caused an adverse reaction. The
number of reports received was
therefore smaller than the number of
drugs involved. The seriousness of
the ADRs is report specific, and
therefore, if a report contained even
one serious reaction, all the adverse
reactions in that report were classi-
fied as serious.
The following information was
collected from the reports: the num-
ber and year of the report, the ATC
Code (4) and name of the drug, the
suspected medicinal substance, the
adverse reaction with a description,
the extent of the reaction (severe or
not severe), and the reporter (doctor
or MPharm). The seriousness of the
reactions was displayed in parallel in
order to draw comparisons among
the reporting groups. The crossprod-
uct relationships and confidence in-
tervals were calculated as a measure
of their concordance.  
Results
During the study period, the number
of reports submitted by MPharms
was smaller than that by doctors.
Annually, about 40% of all the
ADR reports are filled in by
MPharms and about 60% by doc-
tors (Table and Fig. 1).
ADR Reports
The ADR reports differed with re-
gard to psychiatric adverse reac-
tions: their share of all ADRs in
1996 totalled 6% of all reports by
MPharms, whereas their share in the
reports by doctors was about 11%.
The number of reports submitted by
Reports on adverse drug reactions 
– who sends them?
Satu Saarinen
M SC. (PHARM.)
Kaisaniemi Pharmacy
The number of  ADR reports  per  report ing group in the Netherlands
MsPharms Doctors
n % n %
1995 887 37,5 1 481 62,5
1996 1 408 46,3 1 634 53,7
1997 1 627 44,9 2 000 55,1
1998 1 437 44,5 1 794 55,5
1999 1 315 41,6 1 843 58,4
2000 1 218 41,6 1 713 58,4
Total /mean    7  892 43,0         10 465          57,0
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both groups remained approximate-
ly the same in 1997 (5% by
MPharms and 12% by doctors). The
difference became smaller later on:
in 2000, the share of psychiatric ad-
verse reactions among the reports
submitted by MPharms amounting
to about 6%, and those by doctors
to about 8%. Dermatological ad-
verse reactions and reactions relat-
ing to the subcutaneous tissue were
reported more often by MPharms
than by doctors. In 1997 their num-
ber among the reports given by
MPharms was about a fifth, whereas
they were involved in about every
seventh report made by doctors. The
difference remained the same in later
years (1998–2000).
Drugs involved in the ADR 
reports 
In 1995 there were only slight dif-
ferences between the drugs reported
by MPharms and those by doctors.
From 1996 to 1999 there were sig-
nificant differences between two
groups of medical substances: car-
diovascular drugs (ATC Code C)
and antiparasitic products, insecti-
cides and repellants (ATC Code P).
Code P includes e.g. mefloquine, an
antimalarial. Serious CNS adverse
reactions caused by mefloquine were
widely discussed in the media and
professional journals during
1996–1997. As a result of this the
reports of adverse reactions to
mefloquine increased rapidly during
those years.
MPharms reported more ADRs
associated with cardiovascular drugs
than doctors did, whereas doctors
reported more reactions associated
with antiparasitic products, insecti-
cides and repellants than did the
MPharms. Every fourth ADR report
submitted by MPharms in 1996 in-
volved cardiovascular drugs, where-
as the corresponding figure for doc-
tors was every sixth. ADRs associat-
ed with the use of antiparasitic
products, insecticides and repellants
were reported in a contrary way;
they accounted for only about 4%
of the reports by MPharms, whereas
the corresponding figure for doctors
was about 18%. In 1997 the differ-
ence was even bigger: 3% versus
23%.
Seriousness of the ADRs 
The differences between the report-
ing practices of MPharms and doc-
tors in relation to severe ADRs in-
creased between 1995 and 2000. In
1995 MPharms and doctors report-
ed an approximately equal number
of severe ADRs, but in 2000 about
9% of all reports by MPharms and
about 23% of all reports by doctors
were associated with severe adverse
reactions (Fig. 2). Statistically, the
difference was significant every year
after 1995.
Conclusion
Fewer ADRs in general were report-
ed by MPharms than by doctors,
which may be due to the fact that
MPharms are fewer in number than
are doctors. MPharms also reported
fewer severe ADRs compared with
doctors.
There were also differences be-
tween the ADRs reported by the
two groups. It may be explained by
the assumption that patients suffer-
ing from psychiatric adverse reac-
tions will perhaps prefer to discuss
them t with their doctors. Such reac-
tions are usually related to prescrip-
tion drugs, in which case the patient
already has an established relation-
ship with the doctor. Dermatological
complications are easier to talk
about in the pharmacy.
According to previous studies,
there are two kinds of beliefs on
how the reporting of serious ADRs
is shared between the MPharms and
the doctors. On one hand, a study
carried out on hospital doctors and
MPharms revealed that MPharms
are more frequently inclined to re-
port serious ADRs than doctors are
(5, 6). On the other hand, according
to a recent Dutch study, doctors
were the ones who reported more
frequent serious ADRs (3) in exactly
the same way as this study shows.
In the Netherlands only less than
1% of all reports by MPharms origi-
nate from hospitals. Consequently,
efforts are made by Lareb to encour-
age hospital MPharms to make
more frequent reports.
Even though the participation of
personnel with pharmaceutical train-
ing in the reporting of ADRs should
be studied worldwide, the general
opinion is that all countries should
accept reports from them as well.
Several studies have concluded that
people with pharmaceutical training
play an active part in the ADR mon-
itoring (6).
It is not, however, always as
straightforward as that. The most
important reason for pharmacists
and MPharms in Finland being un-
able to give reports on adverse reac-
tions of drugs is based on the gener-
al principles of the drug supervisory
authorities. Limited resources are
considered better utilised when the
ADR reporting is concentrated on
serious ADR reports mainly from
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medical doctors. In any case, if a pa-
tient is suffering from a serious ad-
verse reaction he/she is likely to con-
tact a doctor. Consequently, the ad-
verse reactions reported to the phar-
macy would not, in the main, be se-
rious ones, but ones previously
known. Receiving a great number of
reports of this type is probably un-
likely to be useful, since the purpose
of ADR reports is to obtain new or
important information on drug safe-
ty. Should there be the intention to
include pharmacy personnel in the
reporting practice of ADRs, it needs
first of all to be established how and
to what extent it would be possible
to carry this out sensibly, and what
is aimed at in achieving it.
As ADR reporting is voluntary,
the pharmacy personnel would need
time to become familiar with the
routine, and consequently, the use of
resources available at pharmacies
should be considered. Patient
records are often required as enclo-
sures to ADR reports. In a regular
pharmacy this may be complicated
and time-consuming and require
contact with the patient’s doctor.
Hospital pharmacies may perhaps
be more appropriate locations for
training pharmacy personnel in the
monitoring of adverse reactions and
submitting of reports. A doctor
would then be available if necessary,
and monitoring of the patient’s con-
dition would be easier than in a reg-
ular pharmacy. At the same time,
use could be made of the developing
sector of pharmacy facilities avail-
able on the wards.
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